Cancer Chemotherapy and Pharmacology

, Volume 7, Issue 1, pp 11–14 | Cite as

High-dose dexamethasone for prevention of cis-platin-induced vomiting

  • Matti S. Aapro
  • David S. Alberts
Original Articles Dexamethasone CDDP-induced Vomiting

Summary

Severe, debilitating nausea and vomiting are seen in almost 100% of patients treated with cis-platinum. These side-effects can be so severe and prolonged as to preclude therapy in a large number of patients. Commonly used antiemetics have had only limited success in controlling cis-platinum-induced nausea and vomiting. Various reports have indicated benefits from steroids in this setting.

We have tested a high-dose dexamethasone regimen with or without neuroleptics, which inhibits chemotherapy-induced vomiting in 50% of patients failing with prior antiemetics and in 71% of those who had not received prior antiemetics. This treatment was administered on an out-patient basis as it involved oral administration of the antiemetic.

Neuroleptic therapy was not randomly assigned, but the results of this pilot study suggest that it did not enhance dexamethasone's efficacy. There were no significant side-effects due to the steroids. The antiemetic effectiveness of dexamethasone was retained through repeated courses of chemotherapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baker JJ, Lokey JL, Price NA, Winokur SH, Bowen J, Taylor A (1979) Letter. N Engl J Med 301: 728Google Scholar
  2. 2.
    Bhakoo HS, Paolini NS, Milholland RJ, Lopez RE, Rosen F (1981) Glucocorticoid receptors and the effect of glucocorticoids on the growth of B-16 melanoma. Cancer Res 41: 1695–1701Google Scholar
  3. 3.
    Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky C, Simon RM, Rosenberg SA (1979) Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate; a prospective randomized evaluation. Ann Intern Med 91: 819–824Google Scholar
  4. 4.
    Drapkin R, McAloon E, Sokol G, Paladine W, Marks R (1981) The antiemetic effect of dexamethasone in patients receiving cis-platinum. Proc ASCO 22: 340Google Scholar
  5. 5.
    Einhorn LH, Williams SD (1979) The role of cis-platinum in solid-tumor therapy. N Engl J Med 300: 289–291Google Scholar
  6. 6.
    Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P (1979) Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust 2: 657–659Google Scholar
  7. 7.
    Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connell MJ, Schutt AJ, Schwartao NW (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy: A comparison with prochlorperazine and a placebo. Ann Intern Med 91: 825–830Google Scholar
  8. 8.
    Frytak S, Moertel CG, Eagan RT, O'Fallon JR (1981) A double-blind comparison of metoclopramide and prochloperazine as antiemetics for platinum therapy. Proc ASCO 22: 350Google Scholar
  9. 9.
    Gralla RJ, Squillante A, Itri LM, Pisko S, Kelsen DP, Young CW (1981) High-dose metoclopramide: Effective antiemetic against cis-platin in randomized trials vs placebo and prochlorperazine. Proc ASCO 22: 344Google Scholar
  10. 10.
    Grossman B, Lessin LS, Cohen P (1980) Droperidol prevents nausea and vomiting from cis-platinum. N Engl J Med 301: 47Google Scholar
  11. 11.
    Gylys JA, Doran KM, Buyniski JP (1979) Antagonism of cis-platin induced emesis in the dog. Res Commun Chem Pathol Pharmacol 23: 61–68Google Scholar
  12. 12.
    Haid M (1981) Steroid antiemetics may be harmful. N Engl J Med 304: 1237Google Scholar
  13. 13.
    Herman TS, Einhorn LH, Jones SE, Magy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300: 1295–1297Google Scholar
  14. 14.
    Kahn T, Elias EG, Mason GR (1978) A single dose of metloclopramide in the control of vomiting from cis-dichloro-diammineplatinum (II) in man. Cancer Treat Rep 62: 1106–1107Google Scholar
  15. 15.
    Lee BJ (1981) Methylprednisolone as an antiemetic. N Engl J Med 304: 486Google Scholar
  16. 16.
    Levitt M, Wilson A, Bowman D, Faiman C, Kemel S, Krepart G, Schipper H, Weinerman B, Weinerman R (1981) Dose vs response of tetrahydrocannabinol vs prochlorperazine as chemotherapy antiemetics. Proc ASCO 22: 352Google Scholar
  17. 17.
    Loeser EA, Bennett G, Stanley TH, Machin R (1979) Comparison of droperidol, haloperidol, and prochlorperazine as postoperative antiemetics. Can Anaesth Soc J 26: 125–127Google Scholar
  18. 18.
    Moertel CG, Reitemeier RJ (1969) Controlled clinical studies of orally administered drugs. Gastroenterology 57: 262–268Google Scholar
  19. 19.
    Neidhardt J, Gagen M, Metz E (1980) Haldol is an effective antiemetic for platinum- and mustard-induced vomiting when other agents fail. Proc ASCO 21: 365Google Scholar
  20. 20.
    Orr LE, McKernan JF, Bloome B (1980) Antiemetic effect of tetrahydrocannabinol, compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 140: 1431–1433Google Scholar
  21. 21.
    Plotkin DA, Plotkin D, Okum R (1973) Haloperidol in the treatment of nausea and vomiting due to cytotoxic drug administration. Curr Ther Res 15: 599–602Google Scholar
  22. 22.
    Rich WM, Abdulhayoglu G, DiSaia PJ (1980) Methylprednisolone as an antiemetic during cancer chemotherapy — a pilot study. Gynecol Oncol 9: 193–198Google Scholar
  23. 23.
    Robins IH, Ershler WB, DeJongh L, Chang YC, Drozdowicz PM, Carr BI, Meyer DK (1979) Antiemetic effect of intravenous diazepam in patients receiving cis-diamminedi-chloroplatinum II. A pilot study. Pediatr Oncol 27: 247–249Google Scholar
  24. 24.
    Rosenberg B (1975) Possible mechanisms for the antitumor activity of platinum coordination complexes. Cancer Chem Rep [1] 69: 589–598Google Scholar
  25. 25.
    Sallan SE, Cronin C, Zelen M, Zinberg NE (1980) Antiemetics in patients receiving chemotherapy for cancer, a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 302: 135–138Google Scholar
  26. 26.
    Strum SB, Opfell RW, McDermed JE, Reich LP (1981) Intravenous metoclopramide (MCP) inhibition of cis-platinum (DDP) induced nausea and vomiting. Proc ASCO 22: 231Google Scholar
  27. 27.
    Stryker JA, Demers LM, Mortel R (1979) Prophylactic ibuprofen administration during pelvic irradiation. Int J Radiat Oncol Biol Phys 5: 2049–2052Google Scholar
  28. 28.
    Tornetta FJ (1972) Double-blind evaluation of haloperidol for antiemetic activity. Anesth Analg (Cleve) 51: 964–967Google Scholar
  29. 29.
    Tornetta FJ (1977) A comparison of droperidol, diazepam, and hydroxyzine hydrochloride as premedication. Anesth Analg (Cleve) 56: 496–500Google Scholar
  30. 30.
    Wilson T, Weltz M, Molimando D, Perry D, Baldwin P, Kimball D (1981) Continuous infusion of droperidol: antiemetic therapy for cis-platinum toxicity. Proc ASCO 22: 351Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • Matti S. Aapro
    • 1
  • David S. Alberts
    • 1
  1. 1.The Cancer Center, College of MedicineUniversity of ArizonaTucsonUSA

Personalised recommendations